1.	A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma. Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PX115.1.1-201, NCT00444782
2.	A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C09-315-02, NCT01223209
3.	Radiation Therapy, Tadalafil, Sargramostim, Gemcitabine, and Telomerase Vaccine (GV1001) in Patients With Pancreatic Cancer Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: PHS 10-141B, NCT01342224
4.	GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC) Phase: No phase specified Type: Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: 2006-002646 11, 2006-50 DNR, NCT00509457